← Leaderboards
Rebecca Jean Whelan
University Of Kansas Lawrence
$1,679,630
Attributed
$2,111,587
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $658.2K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,111,587 · 4
By mechanism
T32$863,915 · 1
P20$453,598 · 1
R21$411,983 · 1
R15$382,091 · 1
Top collaborators
- Brian Douglas Ackley2 shared
Most similar at University Of Kansas Lawrence
Same institution · by research overlap
- V Gustavo Blanco$11,554,263
- Gunda I. Georg$26,008,014
- Yong Zeng$5,950,609
- Robert P Hanzlik$12,359,909
- Michail A Alterman$565,338
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanCa-125 AntigenEarly DiagnosisProteinsTumorCancer CellSerumScreening For Ovarian CancerDetectionMalignant Neoplasm Of OvaryOvarian NeoplasmBiological MarkersMalignant NeoplasmsCancer BiomarkersGlycoproteinsFundingGlycosylationMonitorImmunoassayMucinsChemotherapyEpitopesMass Spectrum AnalysisMessenger Rna
Grant awards (9)
Clarifying the roles of glycoprotein sequence and cancer cell phenotype on the immunogenicity of ovarian cancer biomarker CA125$234,837
P20 · FY2025 · GM · contact PI
Graduate Training at the Biology-Chemistry Interface$439,487
T32 · FY2024 · GM
Clarifying the roles of glycoprotein sequence and cancer cell phenotype on the immunogenicity of ovarian cancer biomarker CA125$218,761
P20 · FY2024 · GM · contact PI
Graduate Training at the Biology-Chemistry Interface$424,428
T32 · FY2023 · GM
Targeted proteomics of MUC16 to enable early detection of ovarian cancer recurrence$167,270
R21 · FY2023 · CA · contact PI
Targeted proteomics of MUC16 to enable early detection of ovarian cancer recurrence$219,069
R21 · FY2022 · CA · contact PI
Targeted proteomics of MUC16 to enable early detection of ovarian cancer recurrence$25,644
R21 · FY2022 · CA · contact PI
Development of aptamer-based detection and therapy strategies for ovarian cancer$37,041
R15 · FY2017 · CA · contact PI
Development of aptamer-based detection and therapy strategies for ovarian cancer$345,050
R15 · FY2011 · CA · contact PI